Results 141 to 150 of about 203,299 (265)

Spatially Discontinuous Mutation Topographies in Ductal Carcinoma In Situ Reveal Noncompetitive Growth Dynamics. [PDF]

Cancer Res
Ryser MD, Greenwald MA, Monyak D, Sorribes IC, King L, Hall A, Geradts J, Weaver DL, Mallo D, Holloway ST, Wu E, Murgas KA, West RB, Grimm LJ, Maley CC, Marks JR, Shibata D, Hwang ES.   +17 more
europepmc   +1 more source

The landscape of the intestinal microbiome among patients with newly diagnosed invasive breast cancer and ductal carcinoma in situ (DCIS). [PDF]

NPJ Breast Cancer
Sammons SL, Kuntz TM, DiLullo M, Morgan XC, Martin A, Hughes ME, Rahman T, Barroso-Sousa R, Ogayo ER, Giordano J, Ryan S, Waks AG, Schlam I, Ligibel J, Lin NU, Garrido-Castro AC, Mittendorf EA, Tolaney SM.   +17 more
europepmc   +1 more source

Cold atmospheric plasma‐mediated tumor microenvironment remodeling for cancer treatment

BMEMat, EarlyView.
Schematic presentation of CAP‐mediated TME remodeling. This review summarizes recent efforts in cold atmospheric plasma (CAP) application in cancer treatment, highlighting the anticancer potential of CAP, molecular mechanisms, and future perspectives for further improvement and clinical translation.
Israr Khan, Qiujie Fang, Cao Fei, Ziyuan Wang, Zhaowei Chen, Guojun Chen, Zhiming Xu, Shu Xu, Zhitong Chen   +8 more
wiley   +1 more source

Semaphorin-7A promotes macrophage-mediated mammary epithelial and ductal carcinoma in situ invasion. [PDF]

Breast Cancer Res
Dahms PA, Hinckley B, Prekeris R, Behbod F, Lyons TR.   +4 more
europepmc   +1 more source

Nanomaterials‐mediated glycolysis rewriting to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes cutting‐edge advances in glycolysis‐rewiring nanomedicines, emphasizing their mechanisms in reversing immunosuppression and reinvigorating antitumor immune responses. Challenges in clinical translation and future directions for designing multifunctional metabolic‐immune modulators are also critically discussed ...
Zilin Ma, Songyan Li, Jie Yan, Xuechun Wang, Wen Zhao, Yunxuan Song, Dongdong Liu, Jianwei Jiao, Xiuying Duan, Guiqiang Zhang   +9 more
wiley   +1 more source

Radiation therapy in a ductal carcinoma in situ patient with ornithine transcarbamylase deficiency: a case report. [PDF]

Radiat Oncol J
Kang I, Park J, Yang C, Kim A, Tang M, Lu K, Carr A, Sener SF, McGowan R, Yano S, Yoo SK.   +10 more
europepmc   +1 more source

Theranostic nanoplatform for high‐performance dual‐modal magnetic resonance imaging‐guided therapy of orthotopic hepatocellular carcinoma

BMEMat, EarlyView.
This article introduces a biomimetic Mn‐doped polydopamine nanoplatform (HAMM NPs) coated with cancer cell membranes. It enables targeted hepatocellular carcinoma theranostics via T1/T2 dual‐mode magnetic resonance imaging and tumor microenvironment‐triggered sonodynamic therapy/chemodynamic therapy, achieving potent antitumor efficacy in subcutaneous ...
Jiayin Lin, Wenbo Chen, Xiuqi Hou, Kai Wang, Fan Liu, Ruling Zhang, Zhong Cao, Jian Zheng   +7 more
wiley   +1 more source

Diagnostic value of automated breast volume scanner for breast ductal carcinoma in situ. [PDF]

Medicine (Baltimore)
Tian C, Wu J, Wang Z.
europepmc   +1 more source

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

BMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao, Rui Qu, Zan Dai, Xiqun Jiang, Xu Zhen   +4 more
wiley   +1 more source

Development and validation of a nomogram for differentiating granulomatous lobular mastitis from ductal carcinoma in situ. [PDF]

Front Oncol
Li Y, Su L, Zhang Q, Liu Z.
europepmc   +1 more source